Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8463509 | 0.82 | NQO1 (0.48) | NQO1ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL8463737 | 0.82 | NQO1 (0.58) | NQO1ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL13316967 | 0.79 | NQO1 (0.67) | NQO1ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL60209 | 0.79 | NQO1 (0.67) | NQO1ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL8460261 | 0.78 | NQO1 (0.54) | NQO1ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL3239122 | 0.78 | NQO1 (0.74) | NQO1ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL24300289 | 0.78 | TP53 (0.49) | ALDH1A1SMN1; SMN2KDM4EMAPTTP53 | |
| Hydrochloric Acid SCHEMBL2855974 | 0.77 | NQO1 (0.64) | NQO1ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL14593916 | 0.77 | SLC2A1 (0.53) | ALDH1A1SMN1; SMN2KDM4EMAPTTP53 | |
| SCHEMBL10121182 | 0.75 | LMNA (0.46) | ALDH1A1KDM4EMAPTTP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022084741-A1 | CFTR MODULATOR COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-04-28 | — | — | WO | disclosed |
| US-20210246141-A1 | Pyrazolo[4,3-d]pyrimidines as Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2021-08-12 | — | — | US | disclosed |
| US-10858361-B2 | Pyrazolo[4,3-d]pyrimidines as antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-12-08 | — | — | US | disclosed |
| US-20200255431-A1 | Pyrazolo[4,3-d]pyrimidines as Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2020-08-13 | — | — | US | disclosed |
| US-10689386-B2 | Pyrazolo[4,3-d]pyrimidines as antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-06-23 | — | — | US | disclosed |
| US-10588894-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190276457-A1 | Pyrazolo[4,3-d]pyrimidines as Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2019-09-12 | — | — | US | disclosed |
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC | 2019-03-05 | — | — | US | disclosed |
| US-20190022074-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY Therapeutics LLC | 2019-01-24 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858361-B2 | Pyrazolo[4,3-d]pyrimidines as antitumor agents | RB1, RRM2, RRM2B | NQO1 489/4885ALDH1A1 606/4885SMN1; SMN2 2912/4885 |
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | NQO1 531/4885ALDH1A1 2765/4885SMN1; SMN2 4331/4885 |
| US-20210246141-A1 | Pyrazolo[4,3-d]pyrimidines as Antitumor Agents | RB1, RRM2, RRM2B | NQO1 489/4885ALDH1A1 606/4885SMN1; SMN2 2912/4885 |
| US-10588894-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | NQO1 1527/4885ALDH1A1 3448/4885SMN1; SMN2 3555/4885 |
| US-20190276457-A1 | Pyrazolo[4,3-d]pyrimidines as Antitumor Agents | DPYD, TP53, TYMP | NQO1 1304/4885ALDH1A1 620/4885SMN1; SMN2 2675/4885 |
| US-10689386-B2 | Pyrazolo[4,3-d]pyrimidines as antitumor agents | DPYD, TP53, TYMP | NQO1 1304/4885ALDH1A1 620/4885SMN1; SMN2 2675/4885 |
| US-20200255431-A1 | Pyrazolo[4,3-d]pyrimidines as Antitumor Agents | RB1, RRM2, RRM2B | NQO1 489/4885ALDH1A1 606/4885SMN1; SMN2 2912/4885 |
| US-20190022074-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | NQO1 1527/4885ALDH1A1 3448/4885SMN1; SMN2 3555/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | NQO1 531/4885ALDH1A1 2765/4885SMN1; SMN2 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.